))
FDA Approvals in Relapsed/Refractory CLL Set up "Difficult Choice"
Manage episode 430589189 series 3560609
Sisällön tarjoaa Jacqueline Stone and Oncololgy News Central. Jacqueline Stone and Oncololgy News Central tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
When it comes to the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), "within the last eight months or so, we have had some exciting new events," says Daniel A. Ermann, MD, a hematologist-oncologist and assistant professor at the University of Utah Huntsman Cancer Institute in Salt Lake City. The U.S. Food and Drug Administration approved pirtobrutinib for previously treated CLL in December 2023 and approved the CAR-T therapy lisocabtagene ciloleucel for relapsed/refractory disease in March 2024. These new options for patients with unmet needs present "a difficult choice, and it is a little bit of a balance," Dr. Ermann explains. He discusses key considerations for treatment selection with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles.
124 jaksoa
Jaa
